Monte Rosa Therapeutics, Inc.

NASDAQ:GLUE

Biotechnology

Healthcare
$9.07 -1.39%

-$0.26 today

Market cap
$775.03M
Beta
1.60
P/E (TTM)
-9.1
EPS (TTM)
-$1.98
52W Low $4.12High $25.77

Volume 1.26M

Average 1.02M

GLUE Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Monte Rosa Therapeutics, Inc.NASDAQ: GLUE

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables turns positive

Q1 FY2026 accounts payables was $4.38M, compared with -$10.87M a year earlier. Trailing-twelve-month accounts payables was $1.54M. Over 3 fiscal years it compounded at +164.1% a year.

Context

  • Accounts payables amounted to 11.1% of revenue in FY2025, up 2.8 pp from a year earlier.
  • Accounts payables increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts payables holds near $4.38M or moves back toward the trailing-twelve-month quarterly average of $385.75K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.38M+141.2% QoQ
Last fiscal yearDec 2025
-$13.71M-319.3% YoY
LTMMar 2026
$1.54M+244.4% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+140.3%——
1 year-319.3%——
3-year CAGR+164.1%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
(13.71M) USD
Year-over-year change
-319.3%

Accounts Payables vs competitors

How GLUE compares with its peers on the latest reported figures

  • GLUE's LTM Mar 2026 accounts payables of $1.54M is the 3rd largest of the 4 companies compared; the peer median is $92K.
  • Its year-over-year change of +244.4% is the 2nd highest of 4, against a peer median of +109.7%.
  • Accounts payables amounts to 3.6% of revenue for GLUE, versus a peer median of 3.6%.
GLUE Competitors Peer median
Accounts Payables for GLUE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$25.05M +537.3%—3.6%
ARVNArvinas, Inc.LTM Mar 2026$7.7M -527.8%—8.6%
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$1.54M +244.4%+164.1%3.6%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$92K +109.7%-48.0%0.3%
Peer median (excluding GLUE) $92K+109.7%-48.0%3.6%

Competitors are the stored peer set for GLUE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(73.96M)(108.5M)(135.35M)(72.7M)(38.63M)
Depreciation & Amortization2.13M3.75M6.22M8.12M8.36M
Deferred Income Tax17K0000
Stock-Based Compensation5.2M11.66M16.67M18.13M18.87M
Change in Working Capital6.29M(2.13M)72.47M91.4M(9.19M)
Accounts Receivables0(187)1.9M332K(7M)
Inventory0187000
Accounts Payables(706K)(744K)5.76M6.25M(13.71M)
Other Working Capital6.99M(1.39M)64.81M84.81M11.52M
Other Non-Cash Items960K2.76M(3.81M)(2.95M)(2.2M)
Operating Cash Flow(59.36M)(92.47M)(43.8M)42M(22.8M)
Capital Expenditures(9.73M)(12.91M)(19.04M)(3.99M)(4.7M)
Acquisitions (Net)79K109K62K00
Purchases of Investments0(384.42M)(103.15M)(230.36M)(376.68M)
Sales of Investments0178M210.93M189.9M279.54M
Other Investing Activities00000
Investing Cash Flow(9.65M)(219.22M)88.8M(44.45M)(101.83M)
Debt Repayment00000
Common Stock Issued237.75M20.06M27.49M944K30.35M
Common Stock Repurchased000(641K)0
Dividends Paid00000
Other Financing Activities(3.19M)411K098.59M0
Financing Cash Flow377.56M20.47M27.49M98.89M30.35M
Effect of Forex Changes00000
Net Change in Cash308.55M(291.22M)72.49M96.44M(94.28M)
Free Cash Flow(69.1M)(105.38M)(62.84M)38.01M(27.5M)

Monte Rosa Therapeutics, Inc.

NASDAQ:GLUE

Intrinsic Alpha fair value

Locked

Current Price

$9.07

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.